Clinical trials: Bladder Cancer (BC)
NMIBC
Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer
Research Objective Taking Trop2, a specific target of bladder urothelial carcinoma, as the research basis, this study adopts a Trop2-targeted near-infrared (NIR) fluorescent probe combined with an intravesical rapid incubation…
- Trial name
- NCT07800507
- Testing
- TTP-ICG NIR fluorescent diagnostic agent
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Yunnan Cancer Hospital
Bladder Cancer (BC), Urothelial Carcinoma (UC)
Trop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder Samples
Up to 30% of non-muscle-invasive bladder cancer (NMIBC) lesions may be missed by standard white-light cystoscopy, resulting in high tumor recurrence rate. This is a single-center, single-arm, phase 2 prospective study.
- Trial name
- NCT07848854
- Testing
- TTP-ICG fluorescent probe
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Yunnan Cancer Hospital
Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma
Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis
This is a two-stage, prospective, single-center observational diagnostic accuracy study evaluating noninvasive urine testing for the detection of urothelial carcinoma (UC).
- Conditions
- Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma, UTUC, Bladder Cancer (BC)
- Trial name
- NCT07614594
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Henan Provincial People's Hospital
Bladder Cancer (BC)
Local Radiotherapy for Urinary Bladder Cancer in Patients Not Eligible for Curative Treatment
The goal of this clinical trial is to improve the quality of life and prolong survival in bladder cancer patients unfit for curative treatment.
- Trial name
- LORUP (NCT07524426)
- Testing
- Local hypo fractionated adaptive radiotherapy and Standard of Care, Standard of Care (Investigator Choice)
- Where
- Sweden
- Volunteers
- 248 people
- Sponsor
- Umeå University
Bladder Cancer, CLE
Confocal Laser Endomicroscopy During TransUrethral Resection for Improving BC Diagnosis and Treatment
A prospective monocenter diagnostic accuracy study of Confocal Laser Endomicroscopy (CLE) for Bladder Cancer(BC) to assess two primary objectives: 1.
- Trial name
- CLETUR (NCT05273593)
- Testing
- Confocal Laser Endomicroscopy (CLE)
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic urinary tumors and other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum…
- Trial name
- NCT05393427
- Testing
- BL-B01D1
- Where
- 4 sites in China
- Volunteers
- 4 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)
Feasibility of HISA During TURBT for NMIBC
The goal of this prospective pilot study is to evaluate the safety and feasibility of using heated saline during bladder tumor surgery in patients with non-muscle invasive bladder cancer.
- Conditions
- Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy), Non-muscle Invasive Bladder Cancer (NMIBC), Non-Muscle Invasive Bladder Neoplasms
- Trial name
- NCT07817173
- Testing
- HISA
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- CAMC Health System
Bladder Cancer
Chemoradiotherapy for Recurrent T1G3 Bladder Cancer
To evaluate the short term results of chemoradiation in case of T1G3 BC after BCG failure.
- Trial name
- NCT03274284
- Testing
- chemoradiation
- Volunteers
- 20 people
- Sponsor
- Assiut University
Bladder Cancer (BC)
Outcomes of Definitive Radiotherapy for Bladder Cancer
this is an observational study for patients with non metastatic bladder cancer recieving local radical radiotherapy with curative intent recieving radical dose of radiotherapy with or without chemosensitizer
- Trial name
- NCT07503795
- Testing
- Radiotherapy followed by chemotherapy
- Where
- Egypt
- Volunteers
- 300 people
- Sponsor
- Sohag University
Bladder Cancer (BC)
Safety, Tolerability, and Preliminary Efficacy of KD01 Via Intravesical Instillation in Bladder Cancer (BC)
Recombinant oncolytic adenovirus injection (KD01) is an oncolytic virus product. Its main component is a conditionally replicative recombinant human type 5 adenovirus, where part of the E3 region has been replaced with the gene…
- Trial name
- NCT07359235
- Testing
- KD01(the recombinant oncolytic adenovirus)
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Tongji Hospital
Bladder Cancer (BC)
Trop2-targeting NIR-II Molecular Probe for Guided Identification of Non-Muscle-Invasive Bladder Cancer
Bladder cancer ranks as the fourth most common malignancy among males the United States . Approximately 75% of patients present with non-muscle-invasive bladder cancer (NMIBC).
- Trial name
- NCT06972771
- Testing
- TTP-ICG incubation solution
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Yunnan Cancer Hospital
Urothelial Cancer, Metastatic Urothelial Cancer
BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy
The objective of the study is to evaluate the efficacy and safety of T-bren in participants with HER2 expressing metastatic UC with progression on or after anti-PD-(L)1-based therapy.
- Conditions
- Urothelial Cancer, Metastatic Urothelial Cancer, Bladder Cancer, Bladder Cancer (BC)
- Trial name
- NCT07869836
- Testing
- T-Bren, Dose level 1, T-bren, Dose level 2, Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin)
- Where
- 2 sites in United States
- Volunteers
- 520 people
- Sponsor
- SystImmune Inc.
Bladder Cancer
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
Clinically node positive (cN+) bladder cancer carries a poor prognosis, especially in patients who are unable to receive or fail to respond to neoadjuvant chemotherapy.
- Trial name
- CIRTiN-BC (NCT04779489)
- Testing
- personalized ultrafractionated stereotactic ablative radiotherapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Texas Southwestern Medical Center
Bladder Carcinoma in Situ (CIS)
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
This is a phase III, single-arm, multicenter, international study to assess the efficacy and safety of ONCOFID-P-B following intravesical instillation in adult patients with histologically and cytologically confirmed CIS, with or…
- Trial name
- NCT05024773
- Testing
- ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)
- Where
- 47 sites in United States, France and 4 more
- Volunteers
- 130 people
- Sponsor
- Fidia Farmaceutici s.p.a.